Aireen is an innovative AI-powered medical device dedicated to transforming how healthcare providers detect and manage serious diseases. By leveraging human retina and advanced neural network models, Aireen enables autonomous, precise screening for conditions such as diabetic retinopathy (DR), age-related macular degeneration (AMD), cardiovascular diseases, and neurodegenerative disorders. Why Aireen? Diabetic retinopathy alone affects nearly 30% of the global diabetic population, and with over 537 million people living with diabetes today—a number projected to reach 783 million by 2045—the need for accurate, scalable screening solutions has never been greater. Early detection is key to preventing severe complications like vision loss. Aireen empowers healthcare providers by offering fast, reliable AI-driven analysis without the need for manual interpretation, ensuring critical conditions are identified at their earliest stages.